Validation of Risk Scoring Systems in Ursodeoxycholic Acid–Treated Patients With Primary Biliary Cholangitis
Cumali Efe(Medizinische Hochschule Hannover), Staffan Wåhlin(Karolinska University Hospital), Janett Fischer(Leipzig University), Hirsh D. Trivedi(Beth Israel Deaconess Medical Center), Alexandra Heurgué–Berlot(Inserm), Fredrik Rorsman(Uppsala University Hospital), Emma Nilsson(Skåne University Hospital), Luigi Muratori(University of Bologna), Nurhan Demir(Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi), Henriette Ytting(University of Copenhagen), Thomas D. Schiano(Icahn School of Medicine at Mount Sinai), Johanna Eliasson(University of Copenhagen), Benedetta Terziroli Beretta‐Piccoli(Ente Ospedaliero Cantonale), Ellina Lytvyak(University of Alberta), Fulya Günşar(Ege University), Can Gönen(Haydarpaşa Numune Eğitim ve Araştırma Hastanesi), Ida Henriksson(Örebro University), Murat Kıyıcı(Bursa Uludağ Üni̇versi̇tesi̇), Koray Taşçılar(Friedrich-Alexander-Universität Erlangen-Nürnberg), Murat Aladağ(Inonu University), Kristina Önnerhag(Skåne University Hospital), Ali Rıza Çalışkan(Adıyaman University), Eric M. Yoshida(Vancouver General Hospital), Alan Bonder(Beth Israel Deaconess Medical Center), Claudia Coppo(University of Bologna), Fatema Alalkim(University of British Columbia), Fatih Güzelbulut(Haydarpaşa Numune Eğitim ve Araştırma Hastanesi), Hanns–Ulrich Marschall(University of Padua), Thomas Berg(Leipzig University of Applied Sciences), David Semela(Kantonsspital St. Gallen), Ersan Özaslan(Ankara Numune Eğitim ve Araştırma Hastanesi), Fatih Eren(Bursa Uludağ Üni̇versi̇tesi̇), Paolo Muratori(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Mårten Werner(Umeå University), Aldo J. Montaño‐Loza(University of Alberta), Tuğrul Pürnak(Hacettepe University), Maneerat Chayanupatkul(Chulalongkorn University)
Cited by 48
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
|Gastroenterology|2017|929
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877